EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EVERLAST-A Phase 2a Trial: 16- and 28-Week Results of ORKA-001 in Moderate-to-Severe Plaque Psoriasis

Bruce Strober, Joel M Gelfand, Johann E Gudjonsson, James Krueger, Mark Lebwohl, Joseph F Merola, Heather Lampel, Eugenia Levi, Joana Goncalves, Catherine Munera, Andrew Blauvelt

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s816

DOI: 10.25251/xk7ac737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Bruce Strober und 10 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

ORKA-001 is a novel, extended half-life, humanized IgG1 monoclonal antibody targeting IL-23p19, a validated therapeutic target for the treatment of moderate-to-severe plaque psoriasis. EVERLAST-A (NCT07090330) is a Phase 2a, randomized, placebo-controlled trial evaluating ORKA-001 in adults with moderate-to-severe plaque psoriasis. Here, the primary Week 16 efficacy and safety results from EVERLAST-A are reported, together with Week-28 data demonstrating a favorable safety profile and deepening clinical response over time.

Methods

Adults with moderate-to-severe plaque psoriasis (body surface area ≥10%, Psoriasis Area and Severity Index [PASI] ≥12, Investigator’s Global Assessment [IGA] ≥3) for >6 months were randomized 3:1 to ORKA-001 600 mg or placebo at Weeks 0 and 4. The primary endpoint was PASI100 at Week 16. Following Week 16, placebo participants crossed over to ORKA-001 (blinded) and were dosed with ORKA-001 600 mg at Weeks 16 and 20, while ORKA-001 participants continued through Week 28. The study continues through Week 52 to assess maintenance regimen, durability of response, and long-term safety.

Results

Among 84 randomized participants (ORKA-001, n=63; placebo, n=21), 40/63 (63.5%) ORKA-001–treated participants achieved the primary endpoint of PASI100 at Week 16 compared with 1/21 (4.8%) receiving placebo (p

Zitieren

APA

Strober, B., Gelfand, J. M., Gudjonsson, J. E., Krueger, J., Lebwohl, M., Merola, J. F., Lampel, H., Levi, E., Goncalves, J., Munera, C., & Blauvelt, A. (2026). EVERLAST-A Phase 2a Trial: 16- and 28-Week Results of ORKA-001 in Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, 10(6), s816. https://doi.org/10.25251/xk7ac737

Vancouver

Strober B, Gelfand JM, Gudjonsson JE, Krueger J, Lebwohl M, Merola JF, et al. EVERLAST-A Phase 2a Trial: 16- and 28-Week Results of ORKA-001 in Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s816. doi:10.25251/xk7ac737

BibTeX
@article{Strober2026,
  author = {Strober, Bruce and Gelfand, Joel M and Gudjonsson, Johann E and Krueger, James and Lebwohl, Mark and Merola, Joseph F and Lampel, Heather and Levi, Eugenia and Goncalves, Joana and Munera, Catherine and Blauvelt, Andrew},
  title = {EVERLAST-A Phase 2a Trial: 16- and 28-Week Results of ORKA-001 in Moderate-to-Severe Plaque Psoriasis},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s816},
  doi = {10.25251/xk7ac737}
}
Kostenlos starten →